Solgen Capital

All three founders — Gerald Chaney, Scott Clark, and Avery DeBiasi — sit on the investment committee, according to the firm's website. The partners share general management duties alongside deal origination, execution, and portfolio oversight. Chaney leads the team with 25 years of private investment experience, including building ICG's US business.

Solgen writes both debt and equity. The firm lists senior debt, unitranche, subordinated debt, and preferred and common equity among the securities it provides, according to its website. The capital can be used to back organic growth and acquisition strategies at healthcare companies.

Solgen focuses on lower middle-market healthcare businesses with $2 million to $30 million of EBITDA, writing checks from $10 million to $100 million. The firm does not specify a preference between growth-stage and mature companies, but its senior advisors include operators who have led growth through roll-ups and non-traditional channel expansion.

The website does not detail a sourcing model, but the backgrounds of the founders and senior advisors suggest a relationship-driven pipeline. Gerald Chaney and Scott Clark spent decades in healthcare leveraged finance, while Senior Advisor Al Aria led over $80 billion in healthcare capital deployment across 45 sectors at Capital One and GE Capital.

No. Solgen has not published an AUM figure or disclosed fund closes publicly. The firm does not appear to have released any performance data or vehicle sizing, so its current scale is undetermined.